تداخلات تريهكسيفينيديل

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (نشرة إبراتروبيوم، التداخلات الدوائية)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (نشرة أكليدينيوم، التداخلات الدوائية)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (نشرة أوميكليدينيوم، التداخلات الدوائية)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

…(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (نشرة ترانيلسيبرومين، التداخلات الدوائية)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (نشرة تيوتروبيوم، التداخلات الدوائية)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (نشرة ديفينوكسين وأتروبين، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (نشرة ريفاستيغمين، التداخلات الدوائية)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (نشرة سترات البوتاسيوم، موانع الاستعمال)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (نشرة غلوكاغون، التداخلات الدوائية)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (نشرة غليكوبيرولات، التحذيرات والاحتياطات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (نشرة كينيدين، موانع الاستعمال)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (نشرة ميتوكلوبراميد، التحذيرات والاحتياطات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk… (نشرة إبراتروبيوم وسالبوتامول، التداخلات الدوائية)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (نشرة تريهكسيفينيديل، التحذيرات)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (نشرة تريهكسيفينيديل، التحذيرات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (نشرة إنكوبوتولينوم توكسين A، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (نشرة أوكسيبوتينين، التحذيرات والاحتياطات)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (نشرة أونابوتولينوم توكسين A، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (نشرة بروكاييناميد، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (نشرة بيريدوستيغمين، التحذيرات والاحتياطات)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (نشرة بيلوكاربين، التداخلات الدوائية)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (نشرة بينازيبريل وهيدروكلوروثيازيد، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (نشرة تروسبيوم، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (نشرة تريميثوبنزاميد، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (نشرة توكسين البوتولينوم من النمط A، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis. (نشرة داريفيناسين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (نشرة ديسيكلومين، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (نشرة تريهكسيفينيديل، التحذيرات)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (نشرة ديكستروميثورفان وكينيدين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة ديوتيترابينازين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (نشرة سكسينيل كولين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (نشرة سوغاماديكس، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (نشرة سوليفيناسين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة فالبينازين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (نشرة فيبيغرون، التحذيرات والاحتياطات)

Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (نشرة فيسوتيرودين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (نشرة تريهكسيفينيديل، التحذيرات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (نشرة كاربيدوبا، التحذيرات)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (نشرة تريهكسيفينيديل، التداخلات الدوائية)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (نشرة ميرابيغرون، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (نشرة نيوستيغمين، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. (نشرة بنزتروبين، التحذيرات)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (نشرة تولكابون، الاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (نشرة دونيبيزيل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (نشرة سيفيميلين، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (نشرة غالانتامين، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

NAMZARIC may interfere with anticholinergic medications. (نشرة ميمانتين ودونيبيزيل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)